Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide therapy for MS.

S A Gauthier1, H L Weiner

  • 1Partners MS Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

International MS Journal
|January 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the Statistical Detection of Change Algorithm for Screening Patients with MS with New Lesion Activity on Longitudinal Brain MRI.

AJNR. American journal of neuroradiology·2023
Same author

Quantitative Susceptibility Mapping of Time-Dependent Susceptibility Changes in Multiple Sclerosis Lesions.

AJNR. American journal of neuroradiology·2019
Same author

CLA-supplemented diet accelerates experimental colorectal cancer by inducing TGF-β-producing macrophages and T cells.

Mucosal immunology·2018
Same author

Baseline biomarkers of connectome disruption and atrophy predict future processing speed in early multiple sclerosis.

NeuroImage. Clinical·2018
Same author

Fast and Robust Unsupervised Identification of MS Lesion Change Using the Statistical Detection of Changes Algorithm.

AJNR. American journal of neuroradiology·2018
Same author

Quantitative Susceptibility Mapping of the Thalamus: Relationships with Thalamic Volume, Total Gray Matter Volume, and T2 Lesion Burden.

AJNR. American journal of neuroradiology·2018
Same journal

American academy of neurology annual meeting.

International MS journal·2011
Same journal

Tumour Necrosis Factor Neutralization in MS: A Cautionary Tale.

International MS journal·2011
Same journal

The clinical usefulness of routine MRI assessment.

International MS journal·2011
Same journal

Acute Psychosis as the Initial Presentation of MS: A Case Report.

International MS journal·2011
Same journal

Russell Brains Review of MS.

International MS journal·2011
Same journal

Epstein-Barr Virus and MS:Causality or Association?

International MS journal·2011
See all related articles

Cyclophosphamide shows benefits in multiple sclerosis (MS) by modulating immune responses and reducing inflammation, as seen in MRI scans. However, toxicities limit its use in early MS, reserving it for advanced cases unresponsive to other therapies.

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Cyclophosphamide is studied for multiple sclerosis (MS) treatment.
  • It modulates immune responses, suppressing Th1 and enhancing Th2 activity, contributing to its therapeutic effects in MS.
  • Magnetic resonance imaging (MRI) has improved understanding of its anti-inflammatory impact on MS.

Purpose of the Study:

  • To review the role of cyclophosphamide in multiple sclerosis (MS) treatment.
  • To highlight its immunomodulatory effects and anti-inflammatory properties.
  • To discuss its safety and appropriate patient selection for MS therapy.

Main Methods:

  • Literature review of studies on cyclophosphamide for MS.
  • Analysis of immune response modulation (Th1/Th2).

Related Experiment Videos

  • Evaluation of MRI findings related to treatment efficacy.
  • Assessment of drug toxicity and risk factors.

    • Main Results:

    • Cyclophosphamide demonstrates effective stabilization in selected MS patients.
    • It exhibits significant anti-inflammatory effects, reducing clinical relapses and MRI-detected lesions.
    • Immunomodulation involves suppression of Th1 and enhancement of Th2 responses.

    Conclusions:

    • Cyclophosphamide offers a therapeutic option for actively progressing MS unresponsive to first-line treatments.
    • Its use is limited in early MS due to bladder toxicity and malignancy risk.
    • Careful patient selection and monitoring are crucial for safe and effective cyclophosphamide therapy in MS.